2025-09-23 - Analysis Report
Okay, here's a comprehensive analysis of Transmedics Group Inc. (TMDX) based on the provided data.

**Report: Transmedics Group Inc. (TMDX) Analysis**

**Company Overview:**

Transmedics Group Inc. is a medical technology company pioneering a novel approach to organ transplant therapy.

**1. Performance vs. S&P 500 (VOO)**

*   **TMDX Cumulative Return:** 234.13%
*   **VOO Cumulative Return:** 78.53%
*   **Relative Divergence:**
    *   Current: 153.3
    *   Range: -64.2 to 296.4
    *   Relative Divergence (Current Position within Range): 60.3

**Analysis:** TMDX has significantly outperformed the S&P 500 (VOO). The current divergence of 153.3 is within the historical range, positioned at the 60.3 percentile, indicating a strong, though not unprecedented, outperformance.

**Alpha/Beta Analysis**

| Year       | CAGR   | MDD    | Alpha  | Beta  | Cap(B) |
|------------|--------|--------|--------|-------|--------|
| 2019-2021  | -4.0%  | 63.4%  | -52.0% | 0.0   | 0.7    |
| 2020-2022  | 140.0% | 68.3%  | 138.0% | 0.1   | 2.1    |
| 2021-2023  | 95.0%  | 69.4%  | 77.0%  | 0.2   | 2.8    |
| 2022-2024  | 147.0% | 82.8%  | 121.0% | 0.2   | 2.2    |
| 2023-2025  | 115.0% | 82.8%  | 56.0%  | 0.5   | 4.3    |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate (CAGR) shows substantial growth in recent periods, with the most recent 2-year period (2022-2024) showing the highest growth at 147.0%.
*   **MDD:** The Maximum Drawdown (MDD) is high, indicating significant volatility and risk.
*   **Alpha:** Positive Alpha values indicate the stock has consistently outperformed the market on a risk-adjusted basis.
*   **Beta:** Low Beta values suggest the stock is less correlated with the market, potentially offering diversification benefits.
*   **Cap(B):** Market capitalization has grown over the period

**2. Recent Price Action**

*   **Current Price:** 122.29
*   **Last Market Update:** {'price': 125.15, 'previousClose': 122.29, 'change': 2.34}
*   **5-day Moving Average:** 119.33
*   **20-day Moving Average:** 113.64
*   **60-day Moving Average:** 117.81

**Analysis:** The price is above all moving averages, suggesting an upward trend. The recent market update shows a positive change (2.34), with the price reaching 125.15 after previous close at 122.29, indicating upward momentum.

**3. Market Risk Indicators & Expected Return**

*   **Market Risk Indicator (MRI):** 0.3367 (Low Risk)
*   **RSI:** 60.29 (Approaching Overbought)
*   **PPO:** 1.4164 (Positive Momentum)
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (4 shares - Caution - MRI:0.33)
*   **Delta_Previous_Relative_Divergence (20-day):** 3.5 (+) - Short-term increase
*   **Expected Return:** 68.9% (Long-term, relative to S&P 500)

**Analysis:** The MRI indicates low market risk. The RSI is approaching overbought territory, which could signal a potential pullback. The positive PPO suggests continued positive momentum. The Hybrid Signal suggests a "Buy" signal with caution due to the MRI. The positive change in relative divergence (3.5) over the past 20 days confirms a short-term upward trend. The expected return of 68.9% is significant, indicating a potentially high long-term return compared to the S&P 500.

**4. Recent News & Significant Events**

*   **Mercedes-Benz Partnership:** TransMedics is partnering with Mercedes-Benz to launch an organ transport fleet in Italy, indicating expansion and innovation.
*   **Bull Case & Momentum Stock:** Articles highlight TMDX as a compelling investment with strong momentum.
*   **Insider Ownership:** Insider ownership increased, which can be a positive sign.
*   **Apple initiated, Hershey upgraded:** This news is unrelated to TMDX

**Analysis:** Recent news is predominantly positive, highlighting strategic partnerships, analyst optimism, and increasing insider ownership. This suggests strong confidence in the company's future.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (Mean: 1.70)
*   **Target Price:** Average: 140.67, High: 170.00, Low: 114.00
*   **Recent Rating Changes:** Not specified

**Analysis:** Analysts generally have a "Buy" rating on the stock with an average target price of $140.67, implying potential upside from the current price.

**5. Recent Earnings Analysis**

| 날짜       | EPS  | 예상 EPS |
|------------|------|----------|
| 2025-07-30 | 0.92 | 0.48     |
| 2025-05-08 | 0.7  | 0.29     |
| 2025-02-27 | 0.19 | 0.22     |
| 2024-10-28 | 0.12 | 0.29     |
| 2024-07-31 | 0.35 | 0.21     |

**Analysis:** The company has consistently exceeded EPS estimates in recent quarters, demonstrating strong earnings performance. The most recent EPS of 0.92 significantly beat the expectation of 0.48.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue  | Profit Margin |
|------------|----------|---------------|
| 2025-06-30 | $0.16B   | 61.38%        |
| 2025-03-31 | $0.14B   | 61.47%        |
| 2024-12-31 | $0.12B   | 59.21%        |
| 2024-09-30 | $0.11B   | 55.94%        |
| 2024-06-30 | $0.11B   | 60.59%        |

**Capital and Profitability:**

| Quarter    | Equity   | ROE    |
|------------|----------|--------|
| 2025-06-30 | $0.32B   | 10.97% |
| 2025-03-31 | $0.27B   | 9.64%  |
| 2024-12-31 | $0.23B   | 3.00%  |
| 2024-09-30 | $0.21B   | 2.01%  |
| 2024-06-30 | $0.19B   | 6.42%  |

**Analysis:** Revenue is growing consistently. The profit margins are very high, indicating pricing power and efficient operations. Equity is increasing, and ROE is improving, indicating better profitability and efficient use of capital.

**7. Overall Assessment**

Transmedics Group Inc. (TMDX) appears to be a strong growth stock with significant positive momentum.

*   **Strengths:**
    *   Significant outperformance compared to the S&P 500.
    *   Strong earnings performance, consistently exceeding expectations.
    *   High profit margins and improving ROE.
    *   Positive analyst ratings and target prices.
    *   Positive recent news, including strategic partnerships and insider buying.
    *   Low Market Risk Indicator (MRI).
    *   High expected long-term return relative to the S&P 500.
*   **Weaknesses:**
    *   High Maximum Drawdown indicates considerable volatility.
    *   RSI approaching overbought territory.

**Conclusion:** Based on this analysis, TMDX appears to be a compelling investment opportunity, particularly for investors with a long-term horizon and a tolerance for volatility. However, the approaching overbought RSI and high MDD warrant careful monitoring and risk management.
